Report overview
The exponential rise in the adoption of self-injection devices for the treatment of autoimmune disorders has created a buzz among companies to invest in the development of novel autoimmune disorder drug delivery devices. Due to the leading market products and intense market penetration, Amgen Inc. has been a pioneer in this field and has been a significant competitor in this market.
This report aims to provide a comprehensive presentation of the global market for Autoimmune Disorder Drug Delivery Device, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Autoimmune Disorder Drug Delivery Device. This report contains market size and forecasts of Autoimmune Disorder Drug Delivery Device in global, including the following market information:
Global Autoimmune Disorder Drug Delivery Device Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global Autoimmune Disorder Drug Delivery Device Market Sales, 2018-2023, 2024-2030, (K Units)
Global top five Autoimmune Disorder Drug Delivery Device companies in 2022 (%)
The global Autoimmune Disorder Drug Delivery Device market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Pen Injectors Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Autoimmune Disorder Drug Delivery Device include AbbVie Inc., Amgen Inc., F. Hoffmann- La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Biogen Inc., Merck KGaA, Bayer AG and Johnson & Johnson Services Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We has surveyed the Autoimmune Disorder Drug Delivery Device manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Autoimmune Disorder Drug Delivery Device Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Autoimmune Disorder Drug Delivery Device Market Segment Percentages, by Type, 2022 (%)
Pen Injectors
Auto-Injectors
Prefilled Syringes
Vials
Global Autoimmune Disorder Drug Delivery Device Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Autoimmune Disorder Drug Delivery Device Market Segment Percentages, by Application, 2022 (%)
In-house Manufacturing
Outsourced Manufacturing
Global Autoimmune Disorder Drug Delivery Device Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Autoimmune Disorder Drug Delivery Device Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Autoimmune Disorder Drug Delivery Device revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Autoimmune Disorder Drug Delivery Device revenues share in global market, 2022 (%)
Key companies Autoimmune Disorder Drug Delivery Device sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Autoimmune Disorder Drug Delivery Device sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie Inc.
Amgen Inc.
F. Hoffmann- La Roche Ltd.
Novartis AG
GlaxoSmithKline Plc
Biogen Inc.
Merck KGaA
Bayer AG
Johnson & Johnson Services Inc.
Teva Pharmaceutical Industries Ltd.
Eli Lily and Company
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Outline of Major Chapters:
Chapter 1: Introduces the definition of Autoimmune Disorder Drug Delivery Device, market overview.
Chapter 2: Global Autoimmune Disorder Drug Delivery Device market size in revenue and volume.
Chapter 3: Detailed analysis of Autoimmune Disorder Drug Delivery Device manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Autoimmune Disorder Drug Delivery Device in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Autoimmune Disorder Drug Delivery Device capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
